Suprachoroidal acetonide shows durability at 6 months in uveitic macular edema


We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Michael Singer, MD, discusses a study that investigated the durability of suprachoroidal triamcinolone acetonide for uveitic macular edema.

The study used real-world data collected from the IRIS registry and followed more than 800 patients who received suprachoroidal triamcinolone acetonide for 6 months.

“The first thing we found was that 40% of patients who were included in real-life use had a history of IOP problems or glaucoma, showing that there might be a place for this in these steroid-responsive patients,” Singer said. “The other thing we found was that 75% of people were able to go 6 months or longer without any type of steroid given as a rescue.”

Source link

error: Content is protected !!